Last reviewed · How we verify

Hepatitis B — Treatment Landscape & Competitive Intelligence

Hepatitis B (Infectious Disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Infectious Disease 2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hepatitis B, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vaccine Support Cp Vaccine administration Women and Infants Hospital of Rhode Island vaccine unknown
Hospital-Based Vaccination Pathway hospital-based-vaccination-pathway Pfizer vaccine various pathogens

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Hepatitis B
  2. Women and Infants Hospital of Rhode Island · 1 drug in Hepatitis B

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hepatitis B:

Cite this brief

Drug Landscape (2026). Hepatitis B — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hepatitis-b. Accessed 2026-05-13.

Related